• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Hematology

Axicabtagene ciloleucel improves event-free survival in relapsed or refractory large B-cell lymphoma

byBoaz WongandHarsh Shah
February 28, 2022
in Hematology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with large B-cell lymphoma refractory to first-line therapy receiving axicabtagene ciloleucel (axi-cel) showed improvement in event-free survival compared to patients receiving standard care.

2. Axi-cel was associated with high-grade adverse side effects including cytokine release syndrome and neurologic events.

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for third-line use in refractory large B-cell lymphoma. To investigate its efficacy as a second-line agent, the ZUMA-7 randomized controlled trial enrolled patients with large B-cell lymphoma that did not respond to first-line chemoimmunotherapy within 12 months to either receive axi-cel or standard salvage therapy consisting of high-dose chemotherapy and autologous stem-cell transplantation. The primary outcomes for this study analyzed event-free and overall survival. Adverse events were assessed as a secondary outcome. The study found that patients receiving second-line axi-cel demonstrated a higher proportion of therapy response, which corresponded to a significantly longer median event-free survival than patients receiving standard therapy. However, axi-cel was also associated with a higher rate of severe adverse events with its patients experiencing cytokine release syndrome and neurologic events, although no associated deaths were reported. Overall, this study supports the use of axi-cel as an alternative second-line therapy for refractory patients with large B-cell lymphoma. While therapeutic efficacy was demonstrated, the study warns of limitations such as a lack of analysis on biological factors influencing responses to CAR-T cell therapy and whether all patients in this population would benefit. Moreover, this study did not enroll patients who were refractory or relapsed more than 12 months from receiving initial therapy.

Click to read the study in NEJM 

Relevant Reading: Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

RELATED REPORTS

Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma

CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

In-Depth [randomized controlled trial]: In this international, multi-center, randomized control trial, the ZUMA-7 trial aimed to investigate the efficacy of axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as a second-line treatment. 180 patients with large B-cell lymphoma with the refractory or relapsed disease to first-line chemoimmunotherapy within 12 months in patients with large B-cell lymphoma were randomized in a 1:1 ratio to receive conditioning chemotherapy with a single infusion of axi-cel or standard salvage chemoimmunotherapy at the investigator’s discretion including an opportunity for autologous stem-cell transplantation. The primary endpoint was event-free survival as determined by blinded-central review, which was analyzed using Kaplan-Meier estimates and Cox proportional-hazards models with stratification. Secondary endpoints were progress-free survival, the incidence of adverse events, and treatment kinetics. The results of the study demonstrated that patients receiving axi-cel experienced longer event-free survival times with a median of 8.3 months compared to the control group at 2.0 months (hazard ratio [HR], 0.40; 95% confidence interval [CI], 0.31-0.51; P<0.001). Corresponding estimated event-free survival rates after 2 years were also favorable for the experimental group at 41% vs. 16% in the control. Patients receiving axi-cel demonstrated 1.66 times the percentage of response to therapy. With respect to safety, all patients experienced at last one adverse, but proportions of severe adverse event incidence were comparable between the axi-cel and control groups (91 vs. 83%). 92% of patients receiving axi-cel experienced cytokine release syndrome and 60% experienced a neurologic event; however, no deaths occurred due to these adverse events. Finally, measured plasma CAR-T levels found that levels peak 7 days post-infusion and were detectable in 40% of treated patients after 2 years. Altogether, this study supports the use of axi-cel as second-line therapy following relapse or refractory disease in patients with large-cell lymphoma.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: axicabtagene ciloleucelB-cell lymphomaCAR-T cell therapyCD19relapsed refractory b cell lymphoma
Previous Post

Sintilimab plus anlotinib showed promising clinical and safety response to treat advanced cervical cancer

Next Post

Immediate postpartum intrauterine device insertion associated with increased risk of device expulsion: the APEX-IUD study

RelatedReports

No clinical benefit of specific immunotherapy seen in lymphoma
Pharma

Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma

January 10, 2025
Quick Take: Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study
Oncology

CAR-T Cell Therapy for Relapsed or Refractory High-Risk Neuroblastoma

April 17, 2023
#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma
StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

October 19, 2022
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma
Chronic Disease

Lisocabtagene maraleucel improves survival for relapsed or refractory large B-cell lymphoma

June 29, 2022
Next Post
Family planning providers use long acting contraception more than general population

Immediate postpartum intrauterine device insertion associated with increased risk of device expulsion: the APEX-IUD study

Social media effective adjunct for contraception education

Patients discharged from inpatient psychiatric care may benefit from a text support program

Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Second-line tisagenlecleucel does not improve outcomes in B-cell lymphoma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Intravaginal conjugated oestrogen does not improve continuation rate of ring pessary use
  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.